KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer

Ys, Yang; Sang, Zhenyu; Ma, Jie; Zhu, Yaping; Wu, Sufang

doi:10.21037/tcr-20-2969

Cited by 12 publications

(4 citation statements)

References 69 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the rst part of the study, we illustrated that YWHAE regulated exosome sorting of miR-451a into exosomes. YWHAE promotes cancer progression and can be a potential therapeutic target in multiple cancer types such as breast cancer [19], endometrial cancer [29], and Prostate cancer [30].In this study, we demonstrated that YWHAE transported miR-451a from tumor cells to exosomes. The complex of YWHAE and miR-451a were packed into exosomes leading to the reduction of ESCC cells miR-451a.…”

Section: Discussionmentioning

confidence: 55%

miR-451a was selectively sorted into exosomes and promoted the progression of esophageal squamous cell carcinoma through CAB39

Wang,

Liu,

et al. 2024

Cancer Gene Ther

View full text Add to dashboard Cite

Exosomes are emerging mediators of cell-cell communication, which are secreted from cells and may be conveyed to recipient cells for cell biological processes. Here, we examined exosome miRNA expression in esophageal squamous cell carcinoma (ESCC) cells. We examine different miRNA expressions in cells and exosomes. To study the mechanisms of miRNA packaging into exosomes, we combined exosome proteomic data which is miR-451a interacts with YWHAE. Esophageal squamous tissues and matched tissues were compared from 155 patients, and CAB39 is related to TGF-β1. We found that miR-451a was encapsulated in the exosomes. Overexpression of YWHAE leads to miR-451a accumulation in the exosomes instead of donor cells. Furthermore, CAB39 was targeted with miR-451a. We found that CAB39 weakens antitumor immunity through TGF-β1 in ESCC. In summary, our data demonstrated that YWHAE selectively sorted miR-451a into exosomes and through the target of CAB39 weakened antitumor immunity promotes tumor progression.

show abstract

Section: Discussionmentioning

confidence: 55%

miR-451a was selectively sorted into exosomes and promoted the progression of esophageal squamous cell carcinoma through CAB39

Wang,

Liu,

et al. 2024

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…7 ). Several earlier studies have already confirmed that Sp1 and Sp1 -regulated genes were related to the development of EC [ 27 , 28 ]. Thus, our results indicated that ZBTB4 is a potential target of miR-576-5p and their interaction affects EC cell growth and metastasis.…”

Section: Resultsmentioning

confidence: 82%

miRNA-576-5p promotes endometrial cancer cell growth and metastasis by targeting ZBTB4

2022

View full text Add to dashboard Cite

Purpose MicroRNAs (miRNAs) have already been shown to have a strong correlation with the invasion and metastasis capacity of tumor cells. The present research examined the function of miRNA-576-5p (miR-576-5p) in the development of endometrial cancer (EC). Methods miR-576-5p and ZBTB4 expression in EC and benign endometrial tissues was measured using quantitative real-time PCR (qRT-PCR) and western blot. To evaluate the proliferation ability of tumor cells in vitro, 2,5-diphenyl-2H-tetrazolium bromide (MTT) and colony formation assays were carried out. The effect of miR-576-5p on the proliferation ability of EC cells in vivo was measured by the tumor formation in nude mice. The migration and invasion ability of tumor cells was determined using the transwell assay. To confirm the association between expressions of miR-576-5p and zinc finger and BTB domain containing four (ZBTB4), western blot, qRT-PCR, and luciferase assay were carried out. Results miR-576-5p expression increased significantly in EC samples than in benign endometrial tissues. The level of miR-576-5p was significantly higher in the polymerase ε (POLE) ultramutated subgroup compared to the other three subgroups. High levels of miR-576-5p expression were linked to a shorter progression-free interval time in the copy number high subgroup. Furthermore, upregulated miR-576-5p facilitated EC cell invasion and migration in vitro and promoted the proliferation of EC tumor cell lines both in vitro and in vivo. Moreover, this study showed that the expression of ZBTB4 decreased in patients with EC, and the dual-luciferase reporter assay confirmed that miR-576-5p binds directly to the 3′-UTR of ZBTB4 and inhibits the expression of ZBTB4. An increase in miR-576-5p expression leads to a decrease in the mRNA and protein expression level of ZBTB4. The effects of miR-576-5p can be reversed by overexpression of ZBTB4. Conclusion miR-576-5p promoted proliferation and metastasis capacity of EC cells by inhibiting ZBTB4 expression. We hypothesized that miR-576-5p could be a prospective therapeutic target for EC.

show abstract

“…With the deepening of the understanding of endometrial cancer, clinicians will consider and choose drugs according to different molecular subtypes of endometrial cancer, and MSI-H/dMMR is a very important molecular state. There are several ongoing clinical studies which monoclonal antibodies have been evaluated for the treatment of tumors expressing high levels of immune checkpoint-associated proteins ( 21 - 24 ). The results also indicate that advanced or metastatic stages could benefit from targeted adjuvant therapies based on molecular alterations, particularly considering advanced MSI-H/dMMR ( 21 , 22 ).…”

Section: Discussionmentioning

confidence: 99%

A case series on the efficacy and safety of a PD‐1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI‐H endometrial cancer

Song,

Du,

Xiao

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background Endometrial cancer (EC) is one of the most common gynecological malignancies in developed countries worldwide. The treatment of recurrent endometrial cancer is a very difficult problem in clinical work. Studies on patients with recurrent EC microsatellite instability-high (MSI-H) are very rare. The objective of this study is to initially evaluate the therapeutic effect of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer. Methods Eight patients with recurrent MSI-H endometrial cancer were recruited from Tianjin Medical University Cancer Institute and Hospital from July 2019 to July 2021, and their median age was 55.3 (range, 46–62) years. All patients experienced recurrence after surgical treatment, and the median recurrence and metastasis time was 6.6 (range, 4–10) months. The pathological types were all endometrioid carcinomas. PD-1 inhibitors were selected from camrelizumab or pembrolizumab, and antiangiogenic targeted agents were selected from apatinib or anlotinib. Results The median follow-up time was 11.0 (range, 5–19) months. In the case series, all 8 cases could be evaluated for curative effect with complete response in 4 cases and partial response in 4 cases. The overall objective response rate was 100%. Conclusions PD-1 inhibitors combined with antiangiogenic agents may have good therapeutic effects on patients with recurrent MSI-H endometrial cancer and may become an important method for the treatment of recurrent endometrial cancer in the future.

show abstract

KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer

Cited by 12 publications

References 69 publications

miR-451a was selectively sorted into exosomes and promoted the progression of esophageal squamous cell carcinoma through CAB39

miR-451a was selectively sorted into exosomes and promoted the progression of esophageal squamous cell carcinoma through CAB39

miRNA-576-5p promotes endometrial cancer cell growth and metastasis by targeting ZBTB4

A case series on the efficacy and safety of a PD‐1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI‐H endometrial cancer

Contact Info

Product

Resources

About